Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cyclacel Pharmaceuticals, a biopharmaceutical company, has appointed Nicholas Bacopoulos to its board of directors.
Subscribe to our email newsletter
Dr Bacopoulos’s previous leadership roles include CEO and president of Aton Pharma, where he led the development of Zolinza, approved for the treatment of cutaneous T-cell lymphoma.
Dr Bacopoulos has received his BA degree from Cornell College and his PhD from the University of Iowa. Dr Bacopoulos has completed additional coursework and obtained a postdoctoral fellowship at Yale University School of Medicine.
Spiro Rombotis, president and CEO of Cyclacel, said: “Nicholas Bacopoulos is a valuable addition to Cyclacel’s board of directors bringing extensive knowledge and understanding of the field of oncology.
“His experience with commercialization and product development makes him a strong resource as we advance our clinical pipeline, including our lead drug candidate sapacitabine, currently in Phase II trials for the treatment of elderly patients with acute myeloid leukemia.”